ВестникНОМУС
.
Сборникматериалов
конкурса
литературных
обзоров
-2012
176
21. Hannaford PC et al. Cancer risk among users of oral contraceptives: cohort data
from the Royal College of General Practitioner’s oral contraception study. BMJ
2007; 335 (7621): 651.
22. Harvey A. Risch. Hormonal Etiology of Epithelial Ovarian Cancer, With a
Hypothesis Concerning theRole of Androgens and Progesterone. JNCI JNatl Cancer
Inst (1998) 90 (23): 1774-1786.
23. Heiss G, Wallace R. Health risks and benefits 3 years after stopping randomized
treatment with estrogen andprogestin. JAMA. 2008Mar 5;299(9):1036-45.
24. International Collaboration of Epidemiological Studies of Cervical Cancer,
Appleby P, Beral V.,Cervical cancer and hormonal contraceptives: collaborative
reanalysis of individual data for 16,573 women with cervical cancer and 35,509
women without cervical cancer from 24 epidemiological studies. Lancet. 2007 Nov
10;370(9599):1609-21.
25. Jensen JT et al. Effective treatment of heavy menstrual bleeding with estradiol
valerate and dienogest: a randomized controlled trial. Obstet Gynecol 2011; 117 (4):
777–87.
41/ Kaunitz AM. Oral contraceptive health benefits: Perception versus reality.
Contraception1999; 59: 29S–33S.
26. Jensen J.T. Evaluation of a new estradiol oral contraceptive: estradiol valerate and
dienogest. ExpOpinPharmacother 2010; 11: 7: 1147—1157.
27. Kilic S, Yilmaz N, Erdogan G et al. Effect of non-oral estrogen on risk markers
for metabolic syndrome in early surgically menopausal women. Climacteric 2010;
13:55-62.
28. Koledova VV, Khalil RA. Sex hormone replacement therapy and modulation of
vascular function in cardiovascular disease. Expert RevCardiovasc Ther 2007; 5 (4):
777–89.
29. Korljan B, Bagatin J, Koki
ć
S et al. The impact of hormone replacement therapy
on metabolic syndrome components in perimenopausal women. Med Hypotheses
2010; 74 (1): 162–3.
30. Lech MM, Ostrowska L. Risk of cancer development in relation to oral
contraception. Eur JContrasept ReprodHealthCare 2006; 11 (3): 162–8.
31. LidegaardO et al. Hormonal contraception and risk of venous thromboembolism:
national follow-up study. BMJ 2009; 339: b2890.
32. Louet JF, LeMay C, Mauvais-Jarvis F. Antidiabetic actions of estrogen: insight
fromhuman and geneticmousemodels. CurrAtherosclerRep 2004; 6 (3): 180–5.
